Medical Developments International Limited · ASX:MVP
Medical Developments International — Investor Presentation (August 2016)
41 slides from Medical Developments International's investor presentation, Aug 22, 2016
Slide 1: Medical Developments International Market update
For personal use only Medical Developments International Market update
Slide 2: Vision
Vision For personal use only Medical Developments International (MDI) is a leading Emergency Medicine Company. Our aim is to: 1. Provide unique and innovative products to assist our customers in the management of acute and procedural pain and to dominate the analgesic trauma and minor surgical proce
Slide 3: The Business
The Business For personal use only MDI is delivering two world class “company making” business opportunities. The risk profile of these opportunities is relatively low and well understood. Penthrox: Penthrox has the potential to be the market leader in analgesic markets in the USA, Europe and elsewh
Slide 4: Financial summary of FY16
Financial summary of FY16 For personal use only
Slide 5: Financial summary of FY16: Penthrox
Financial summary of FY16 Penthrox For personal use only ….. Other key highlights • Australian hospitals grew 30% • Australian ambulance business continues to grow • Middle East sales growth of 31%
Slide 6: Key Achievements for Penthrox
Key Achievements for Penthrox For personal use only
Slide 7: Financial summary of FY16: Respiratory
Financial summary of FY16 Respiratory For personal use only Other key highlights • Strong result given New Zealand government contract was not renewed • Sales into Asia grew by more than 70% • New distribution partners in the USA
Slide 8: Key Achievements Respiratory
Key Achievements Respiratory For personal use only
Slide 9: Key Achievements Other
Key Achievements Other For personal use only
Slide 10: Financial summary
Financial summary For personal use only All figures are in AUD$ million unless stated otherwise FY2014 FY2015 FY2016 Total revenue 9.4 11.7 15.5 R & D investment 0.1 0.1 0.1 EBITDA 1.1 2.6 4.3* Net profit 0.9 1.5 1.6 Capital investment 1.9 1.5 6.2 Total assets at 30 June 22.6 23.0 41.2 Total equity
Slide 11: Financial Summary
Financial Summary For personal use only MDI has been profitable every year since listing on the ASX in 2003 and used those profits for registration and additional clinical studies and: • has generated a positive cash flow every year; • pays tax and has paid fully franked dividends; • has received al
Slide 12: MDI Investor Dashboard
MDI Investor Dashboard (ASX: MVP) For personal use only Historical Stock Chart (3 yr) Current stock Price ▲0.200 (3.57%) 5.800 18 Aug, 10:10am Day High 5.800 Day Low 5.650 Open 5.700 Prev. Close 5.600 Volume 72,498 52 Wk. High 6.850 (3 May 2016) 52 Wk. Low 2.100 (25 Aug 2015) Mkt. Cap 330.32 (Mil)
Slide 13: Potential global sales $2 billion+
Penthrox Potential global sales $2 billion+ For personal use only Peak sales in UK estimated to be $72 million per annum* Peak sales in Europe Peak sales in Canada could be estimated to be $250 million $50 million per annum* per annum* Peak sales in Asia Peak sales in USA could be $1 could be $500 b
Slide 14: Value proposition
Penthrox value proposition For personal use only Penthrox can materially improve the Non-narcotic trauma relief, throughput of patients7,8 in the ER. It enables non-addictive, safe.1 better time to analgesia and less medical care and observation compared with Not a restricted medicine narcotics. Pen
Slide 15: New Markets and submissions in FY17 and beyond
Penthrox New Markets and submissions in FY17 and beyond For personal use only Rest of Europe Canada Belgium Russia France Saudi Arabia USA Iraq Korea Taiwan Iran Mexico Latin America Jordon
Slide 16: USA
Penthrox USA For personal use only MVP submitted a detailed regulatory package to the FDA in January 2016. We received a written response from the FDA detailing it’s opinion on the strengths of our regulatory package and by inference the work required to get Penthrox approved for sale in the United
Slide 17: Clinical development program
Penthrox Clinical development program For personal use only Additional clinical trials and studies are planned for FY17 (and beyond) which will broaden the indications for use of Penthrox® including: 1. PIP Study – a European and USA compliant paediatric study. 2. PASS – as Post Authorisation Safety
Slide 18: Intellectual Property
Penthrox Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its manufacturing technology and delivery devices. In the last 12 months MDI has filed and is managing the following patents and trademarks: • 4 Penthrox Inhaler patents • 1 man
Slide 19: Manufacturing
Penthrox Manufacturing For personal use only MDI has invested millions of dollars developing new manufacturing techniques and methods and creating valuable intellectual property. MDI has: 1. Intellectual property. 2. Global production capacity. 3. Lowest cost to manufacture. 4. Significant competiti
Slide 20: Outlook
Penthrox Outlook For personal use only In addition to the global trauma market, MDI has plans to develop applications for its products in the following markets: • Minor Surgical Procedure • Military • Break Through Pain (cancer and post operative) • Home Use trauma • World Aid (no needles, opioid's
Slide 21: Outlook
Penthrox Outlook For personal use only MVP’s ambition is to globalise Penthrox and in doing so make it the main stream analgesic of choice around the world. That process has begun. Over the next 12 months we expect to: 1. Obtain approval to sell Penthrox in the remaining markets in Europe and in a n
Slide 22: Respiratory Devices: Existing distribution network
Respiratory Devices Existing distribution network For personal use only Switzerland Austria Greece UK Germany Canada Belgium Netherlands Italy USA Spain Korea Portugal Malaysia Singapore Hong Kong UAE New Zealand Australia
Slide 23: Respiratory Devices Intellectual Property
Respiratory Devices Intellectual Property For personal use only MDI is protecting its future by generating intellectual property from its new range of respiratory devices. MDI has filed and is a number of global patents and more than 20 international Trade Marks and Registered Designs.
Slide 24: Respiratory Devices Outlook
Respiratory Devices Outlook For personal use only MVP’s ambition is to globalise its Respiratory Devices. That process has begun. We already have partners and make sales in more than 18 countries. Over the next 12 months we expect to: 1. Obtain additional partnership deals in the USA and deliver sal
Slide 25: MDI Corporate Overview
MDI Corporate Overview David Williams Dr Harry Oxer Leon Hoare Max Johnston Allan McCallum Phillip Powell For personal use only Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Non-Executive Chairman Director Director Director Director Director The Managing A Medical Consultant
Slide 26: MDI Global strategy
MDI Global strategy New and revised For personal use only materials and process (lowest cost producer and significant IP) New Business Partners Product innovation (worlds best delivery devices and significant IP) Clinical trials (Commercial clinical studies to support marketing and Regulatory produc
Slide 27: Contact details
Contact details For personal use only HEAD OFFICE 4 Caribbean Drive Scoresby, Victoria, Australia, 3179 Tel: +61 3 9547 1888 Fax: +61 3 9547 0262 Web: www.medicaldev.com
Slide 28: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other
Slide 29: Annexure: About Penthrox
For personal use only Annexure About Penthrox
Slide 30: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Market Leader for trauma pain • Opiate sparing, fast acting inhalational analgesic 1 • 85% of patients reach clinical analgesia within 10 breaths • Is a solution to a significant unmet clinical need • Demonstrated safety and effica
Slide 31: A world class opportunity: Penthrox
Penthrox A world class opportunity For personal use only Penthrox® • Sold in 15 countries around the world including Australia, UK, Europe, South Africa, Singapore with France and Belgium in the coming months. • Major distribution deals signed in Europe and elsewhere in 2015. • $15 million in upfron
Slide 32: Clinical application
Penthrox Clinical application For personal use only Painful procedures Painful procedures Cosmetic Dentistry Surgery • Cutaneous excisions • Burn injuries • Liquid nitrogen • Breaks, Military Consulting removals of skin- fractures and Rooms cancers, warts, etc. dislocations • Invasive • Abdomen pain
Slide 33: Non-narcotic and clinically proven efficacy
Penthrox Non- narcotic and clinically proven efficacy For personal use only VAS scores compared, IV morphine vs IN fentanyl vs Penthrox Summary of mean VAS Pain Scores The criteria for the cross study comparison were a similar study design and endpoint as the Penthrox® Time 0 5 minutes 10 minutes 15
Slide 34: Benefits to medical professionals
Penthrox Benefits to medical professionals For personal use only Rapid onset of Minimal waiting time before a painful procedure can be performed action (3 minutes) and rapid pain relief when a patient is treated for burns, trauma, etc. Inhaled self- Medical professionals can perform a procedure/atte
Slide 35: Benefits over Nitrous Oxide
Penthrox Benefits over Nitrous Oxide For personal use only The benefits of using Penthrox® over Nitrous Oxide include: • Penthrox does not effect vital signs; no clinical depression of respiration or circulation. • Penthrox is self-administered and easy to use. • Penthrox is compact and can be used
Slide 36: Benefits over Morphine
Penthrox Benefits over Morphine For personal use only The benefits of using Penthrox® over Morphine are the same as detailed for Nitrous. In addition there more specific benefits Penthrox has over Morphine include: • Penthrox does not effect vital signs; no clinical depression of respiration or circ
Slide 37: Annexure: About Respiratory Devices
For personal use only Annexure About Respiratory Devices
Slide 38: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI has a long history of investing R&D resources to design and improve respiratory devices used to deliver Asthma and COPD medication. In 2011 MDI launched a new range of products using MDI’s Cross Valve TechnologyTM, a patented system of drug
Slide 39: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only MDI offers a range of devices that can be used to help patients manage and take control of their asthma and COPD. • Space Chamber PlusTM anti-static range • Space Chamber PlusTM aerosol spacer • Space ChamberTM re-usable • Compact Spacer Chamber
Slide 40: MDI Medical Respiratory division
MDI Medical Respiratory division For personal use only Recently approved by the FDA for sale in the USA. Recently approved for full reimbursement in the UK. New distribution partners in the USA (AmerisourceBergen) and first sales. Growing business internationally. MDI now has marketing approvals for
Slide 41: Respiratory division Future
Respiratory division Future For personal use only MDI is investing heavily in developing new and innovative products • Anti static spacers • Anti static mask – (1st of its kind) • Electronic peak flow • Smart phone asthma & COPD applications • Collapsible spacer • Additional patentable devices and t
Medical Developments International — Investor Presentation (August 2016) on 6ix